FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer and Grants Priority Review
Submission Based on PAOLA-1 Trial Which Studied LYNPARZA with Bevacizumab in Women Regardless of Their Biomarker Status Who Responded to…